Paper25154392
Patient-derived xenografts reveal that intraductal carcinoma of the prostate is a prominent pathology in BRCA2 mutation carriers with prostate cancer and correlates with poor prognosis.
Risbridger GP and 16 others. Eur Urol, 2015. Cited by 115 papers, by iCite.
Cite this record
ConductScience Library. Patient-derived xenografts reveal that intraductal carcinoma of the prostate is a prominent pathology in BRCA2 mutation carriers with prostate cancer and correlates with poor prognosis. Papers, record 25154392. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/25154392
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Patient-derived xenografts reveal that intraductal carcinoma of the prostate is a prominent pathology in BRCA2 mutation carriers with prostate cancer and correlates with poor prognosis.
- PubMed
Topics24
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| BRCA2 Protein | Major topic |
| Carcinoma, Intraductal, Noninfiltrating | Major topic |
| Mutation | Major topic |
| Prostatic Neoplasms | Major topic |
| Aged | |
| Animals | |
| Genetic Predisposition to Disease | |
| Heredity | |
| Heterografts | |
| Humans | |
| Incidence | |
| Kaplan-Meier Estimate | |
| Male | |
| Mice, Inbred NOD | |
| Mice, SCID | |
| Middle Aged | |
| Neoplasm Transplantation | |
| Pedigree | |
| Phenotype | |
| Proportional Hazards Models | |
| Prostatectomy | |
| Risk Factors | |
| Time Factors | |
| Treatment Outcome |
Source PubMed
Comments and corrections1
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
| Kind | PMID | Title | In Papers |
|---|---|---|---|
| Comment in | 25194910 | A better understating of the morphological features and molecular characteristics of intraductal carcinoma helps clinicians further explain prostate cancer aggressiveness. | https://conductscience.org/library/papers/25194910 |
Source PubMed
Cited by69
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 115 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42897296 | Rare prostate cancer histologies: detection, characteristics and treatment. | Nat Rev Urol | 2026 | https://conductscience.org/library/papers/42897296 | PubMed |
| 42855542 | Cribriform and intraductal carcinoma in prostate cancer - implications for risk stratification and therapeutic decision-making. | Nat Rev Urol | 2026 | https://conductscience.org/library/papers/42855542 | PubMed |
| 42806037 | Clinical and MRI characteristics of germline pathogenic variant carriers diagnosed with prostate cancer. | Eur Radiol | 2026 | https://conductscience.org/library/papers/42806037 | PubMed |
| 40452312 | Intraductal carcinoma of the prostate: A comprehensive literature review focused on grading challenges and controversies. | Histol Histopathol | 2025 | https://conductscience.org/library/papers/40452312 | PubMed |
| 39937427 | Prospective observational study on the relationships between genetic alterations and survival in Japanese patients with metastatic castration-sensitive prostate cancer: the impact of IDC-P. | Int J Clin Oncol | 2025 | https://conductscience.org/library/papers/39937427 | PubMed |
| 39840193 | Genetic Analysis of Intraductal Carcinoma of the Prostate Detected in High-Grade Prostatic Intraepithelial Neoplasia Cases. | Cureus | 2024 | https://conductscience.org/library/papers/39840193 | PubMed |
| 39465570 | Assessing the predictive value of intraductal carcinoma of the prostate (IDC-P) in determining abiraterone efficacy for metastatic hormone-sensitive prostate cancer (mHSPC) patients. | Prostate | 2025 | https://conductscience.org/library/papers/39465570 | PubMed |
| 39254403 | Histopathological evaluation and grading for prostate cancer: current issues and crucial aspects. | Asian J Androl | 2024 | https://conductscience.org/library/papers/39254403 | PubMed |
| 38893122 | Cribriform versus Intraductal: How to Determine the Difference. | Cancers (Basel) | 2024 | https://conductscience.org/library/papers/38893122 | PubMed |
| 38736618 | Cribiform and intraductal carcinoma in hereditary prostate cancer: clinical and pathological analysis of 20 cases. | Am J Clin Exp Urol | 2024 | https://conductscience.org/library/papers/38736618 | PubMed |
| 38732035 | Unveiling the Genomic Landscape of Intraductal Carcinoma of the Prostate Using Spatial Gene Expression Analysis. | Int J Mol Sci | 2024 | https://conductscience.org/library/papers/38732035 | PubMed |
| 38539432 | Intraductal Carcinoma of the Prostate versus Simulants: A Differential Diagnosis Growing in Clinical Impact. | Cancers (Basel) | 2024 | https://conductscience.org/library/papers/38539432 | PubMed |
| 38417222 | Identification of recurrent BRAF non-V600 mutations in intraductal carcinoma of the prostate in Chinese populations. | Neoplasia | 2024 | https://conductscience.org/library/papers/38417222 | PubMed |
| 38379333 | Molecular complexity of intraductal carcinoma of the prostate. | Cancer Med | 2024 | https://conductscience.org/library/papers/38379333 | PubMed |
| 38339274 | Molecular Mechanisms of Prostate Cancer Development in the Precision Medicine Era: A Comprehensive Review. | Cancers (Basel) | 2024 | https://conductscience.org/library/papers/38339274 | PubMed |
| 38067216 | Molecular Alterations in Intraductal Carcinoma of the Prostate. | Cancers (Basel) | 2023 | https://conductscience.org/library/papers/38067216 | PubMed |
| 37732318 | Mutational spectrum of DNA damage and mismatch repair genes in prostate cancer. | Front Genet | 2023 | https://conductscience.org/library/papers/37732318 | PubMed |
| 37511177 | DNA Damage Repair Pathways in Prostate Cancer: A Narrative Review of Molecular Mechanisms, Emerging Biomarkers and Therapeutic Targets in Precision Oncology. | Int J Mol Sci | 2023 | https://conductscience.org/library/papers/37511177 | PubMed |
| 37408208 | Recent Research Advances in Double-Strand Break and Mismatch Repair Defects in Prostate Cancer and Potential Clinical Applications. | Cells | 2023 | https://conductscience.org/library/papers/37408208 | PubMed |
| 37307876 | Predicting Prostate Cancer Molecular Subtype With Deep Learning on Histopathologic Images. | Mod Pathol | 2023 | https://conductscience.org/library/papers/37307876 | PubMed |
Genes1
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes |
|---|---|---|---|
| BRCA2 | 675 | PubTator's text mining | https://conductscience.org/library/genes/675 |
Source NCBI Gene
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- References
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/25154392
GET https://conductscience.org/api/papers/v1/25154392/cited_by?page=2